Patent application number | Description | Published |
20120309682 | SUPPRESSION OF CANCER METASTASIS - Methods are provided for suppressing cancer metastasis. Cancer metastasis is the most common cause of treatment failure and death in cancer patients. Tumor cell invasion and/or migration can be significantly inhibited after fibrillar proteins (rVP1, F-HSA, and F-BSA) treatment in vitro. In addition, rVP1 can significantly suppress murine and human breast cancer metastasis and human prostate and ovarian cancer metastasis in vivo while F-HSA can significantly suppress murine breast cancer metastasis. Compositions of fibrillar proteins as anti-cancer metastasis therapeutics and methods of use thereof are provided herein. | 12-06-2012 |
20130123183 | Anti-tumor Fibrillar Human Serum Albumin Methods and Compositions - Fibrillar human serum albumin was shown to be effective in the treatment of various types of cancers. Methods and compositions are disclosed for using fibrillar human serum albumin as a medicament to treat subjects having cancer. | 05-16-2013 |
20140350100 | GLUCAGON-LIKE PEPTIDE 1 (GLP-1) RECEPTOR MODULATORS AND USES THEREOF IN REGULATING BLOOD GLUCOSE LEVELS - The present disclosure provides novel glucagon-like peptide-1 (GLP-1) receptor modulators such as compounds of Formula (I) or (II), and pharmaceutically acceptable salts thereof. The present disclosure also provides pharmaceutical compositions, kits, and uses that involve the GLP-1 receptor modulators for regulating blood glucose levels and/or treating diabetes via, e.g., modulating the endogenous signaling pathways mediated by the GLP-1 receptor. | 11-27-2014 |
20150197480 | GLUCAGON-LIKE PEPTIDE 1 (GLP-1) RECEPTOR MODULATORS AND USES THEREOF IN REGULATING BLOOD GLUCOSE LEVELS - The present disclosure provides novel glucagon-like peptide-1 (GLP-1) receptor modulators such as compounds of Formula (I) or (II), and pharmaceutically acceptable salts thereof. The present disclosure also provides pharmaceutical compositions, kits, and uses that involve the GLP-1 receptor modulators for regulating blood glucose levels and/or treating diabetes via, e.g., modulating the endogenous signaling pathways mediated by the GLP-1 receptor. | 07-16-2015 |
Patent application number | Description | Published |
20120058460 | SLUG CONTROL DURING THERMAL CYCLING - The present invention, in one aspect, provides methods and systems for controlling slugs using temperature dependent fluorescent dyes. In some embodiments, the present invention uses one or more techniques to enhance the visibility of slugs, enhance a system's ability to differentiate between slugs, and enhance a system's ability to identify the positions of slugs. | 03-08-2012 |
20130217104 | MICROFLUIDIC CHIP FEATURES FOR OPTICAL AND THERMAL ISOLATION - A microfluidic chip includes microfluidic channels, elements for thermally and optically isolating the microfluidic channels, and elements for enhancing the detection of optical signal emitted from the microfluidic channels. The thermal and optical isolation elements may comprise barrier channels interposed between adjacently-arranged pairs of microfluidic channels for preventing thermal and optical cross-talk between the adjacent microfluidic channels. The isolation element may alternatively comprise reflective film embedded in the microfluidic chip between the adjacent microfluidic channels. The signal enhancement elements comprise structures disposed adjacent to the microfluidic channels that reflect light passing through or emitted from the microfluidic channel in a direction toward a detector. The structures may comprise channels or a faceted surface that redirects the light by total internal reflection or reflective film material embedded in the microfluidic chip. | 08-22-2013 |
20140038191 | OPTICAL SYSTEM FOR HIGH RESOLUTION THERMAL MELT DETECTION - This invention relates to systems and methods for imaging sample materials within a microfluidic device during an assay reaction process. In accordance with certain aspects of the invention, images are formed with a pixel array and a region of interest (“ROI”) is defined within the pixel array. Image values, such as fluorescent intensity, can be computed as averages of individual pixel values within the ROI. Where the ROI is subject to non-uniform conditions, such as non-uniform heating, the ROI can be divided into sub-ROIs which are sufficiently small that the condition is uniform within the sub-ROI. | 02-06-2014 |
20150069045 | THERMAL CONTROL SYSTEMS AND METHODS USING THERMALLY GUARDED MULTIPLEXED SENSORS - Methods and systems for thermal control of a device are disclosed having (i) a heated zone including two or more resistive sensors and (ii) a common electrode connected to each of the two or more resistive sensors. The two or more resistive sensors may be driven with heater control signals having alternating polarities. One or more portions of a thermal boundary of the heated zone may be heated by one or more thermal guard heaters. | 03-12-2015 |
20150118738 | MICROFLUIDIC CHIP FEATURES FOR OPTICAL AND THERMAL ISOLATION - A microfluidic chip includes microfluidic channels, elements for thermally and optically isolating the microfluidic channels, and elements for enhancing the detection of optical signal emitted from the microfluidic channels. The thermal and optical isolation elements may comprise barrier channels interposed between adjacently-arranged pairs of microfluidic channels for preventing thermal and optical cross-talk between the adjacent microfluidic channels. The isolation element may alternatively comprise reflective film embedded in the microfluidic chip between the adjacent microfluidic channels. The signal enhancement elements comprise structures disposed adjacent to the microfluidic channels that reflect light passing through or emitted from the microfluidic channel in a direction toward a detector. The structures may comprise channels or a faceted surface that redirects the light by total internal reflection or reflective film material embedded in the microfluidic chip. | 04-30-2015 |
20150182966 | FIELD DEPLOYABLE SMALL FORMAT FAST FIRST RESULT MICROFLUIDIC SYSTEM - A field-deployable small format microfluidic system includes simplified, low-cost system control elements, optics, fluid control, and thermal control. An embodiment of a microfluidic chip includes a first plate having reagent wells and pneumatic ports formed therein, a second plate with reaction wells and microfluidic channels connecting each reaction well with one reagent well and one pneumatic port formed therein, and a printed circuit board with heater elements, a temperature sensor, and thermal vias providing thermal transfer through the PCB. In one embodiment, the reaction wells, pneumatic ports, reaction wells, and thermal vias are formed symmetrically with respect to a geometric center of the microfluidic chip to promote thermal uniformity across the reaction wells. | 07-02-2015 |
20150182967 | PRINTED CIRCUIT BOARD DESIGNS FOR LAMINATED MICROFLUIDIC DEVICES - A microfluidic device is disclosed including a printed circuit board (PCB) and a microfluidic layer attached to the PCB. The microfluidic layer may include a microfluidic feature. The PCB may include laminated non-conductive and conductive layers. The PCB may also include an electronic component embedded in the laminated non-conductive and conductive layers. A non-conductive layer of the non-conductive layers may be configured to fluidically isolate the electronic component from fluid in the microfluidic feature. The electronic component may be connected to a conductor of a conductive layer of the conductive layers. The PCB may have a fiberglass core or a metal core, which may spread heat to the microfluidic feature. One or more of the conductive layers may be made with heavy copper or extreme copper, and the heavy or extreme copper may spread heat to the microfluidic feature. | 07-02-2015 |
Patent application number | Description | Published |
20100209489 | Formulations of desvenlafaxine - Controlled release formulations of active compounds with pH-dependent solubility are provided. The formulations comprise solubility modulators which minimize the influence of environment on the solubility of the active compounds. | 08-19-2010 |
20110244042 | STABILIZED FORMULATIONS OF CNS COMPOUNDS - Formulations of molindone having superior stability and methods of administering same are provided. The formulations may be immediate, modified, or otherwise delayed release formulations of molindone. | 10-06-2011 |
20110251198 | METHODS FOR PRODUCING VILOXAZINE SALTS AND NOVEL POLYMORPHS THEREOF - Provided here are methods of manufacture of viloxazine and its various salts, as well as viloxazine-related compounds, such as novel intermediate reaction products and polymorphs thereof. In particular, the methods provide a substantially pure API of viloxazine HCl while avoiding undesirable impurities. The methods further provide for separating, identifying, and characterizing novel polymorphs of viloxazine. Further provided are methods for synthesis and identification and characterization of novel intermediates of viloxazine, as well as for some important metabolites and precursors of metabolites of viloxazine. | 10-13-2011 |
20110287099 | Sustained-release formulations of topiramate - Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided. | 11-24-2011 |
20110287103 | Sustained-release formulations of topiramate - Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided. | 11-24-2011 |
20120231085 | CONTROLLED RELEASE COMPOSITIONS OF GAMMA-HYDROXYBUTYRATE - The present invention is directed to oral pulse-release pharmaceutical dosage form containing an immediate release component of gamma-hydroxybutyric acid, and one or more delayed/controlled release components of gamma-hydroxybutyric acid. | 09-13-2012 |
20120321708 | SUSTAINED-RELEASE FORMULATIONS OF TOPIRAMATE - Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided. | 12-20-2012 |
20140037745 | CONTROLLED RELEASE COMPOSITIONS OF GAMMA-HYDROXYBUTYRATE - The present invention is directed to oral pulse-release pharmaceutical dosage form containing an immediate release component of gamma-hydroxybutyric acid, and one or more delayed/controlled release components of gamma-hydroxybutyric acid. | 02-06-2014 |
20140081020 | METHODS OF PRODUCING MOLINDONE AND ITS SALTS - The present invention is directed towards novel methods of synthesis of molindone, synthesis of the intermediates of molindone, and high-purity compositions of molindone. In particular, the invention relates to the methods of synthesis of molindone through the Mannich reaction. | 03-20-2014 |
20140322343 | SUSTAINED-RELEASE FORMULATIONS OF TOPIRAMATE - Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided. | 10-30-2014 |
20150017249 | SUSTAINED-RELEASE FORMULATIONS OF TOPIRAMATE - Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided. | 01-15-2015 |
20150024055 | ENHANCED IMMEDIATE RELEASE FORMULATIONS OF TOPIRAMATE - The present invention provides enhanced immediate release formulations of topiramate, in which 80% of the active ingredient is released in the period of time of not more than 30 min. These formulations may be advantageously used for the treatment of acute neurological conditions, such as migraine. | 01-22-2015 |
20150086629 | STABILIZED FORMULATIONS OF CNS COMPOUNDS - Formulations of molindone having superior stability and methods of administering same are provided. The formulations may be immediate, modified, or otherwise delayed release formulations of molindone. | 03-26-2015 |
20150126735 | METHODS FOR PRODUCING VILOXAZINE SALTS AND NOVEL POLYMORPHS THEREOF - Provided here are methods of manufacture of viloxazine and its various salts, as well as viloxazine-related compounds, such as novel intermediate reaction products and polymorphs thereof. In particular, the methods provide a substantially pure API of viloxazine HCl while avoiding undesirable impurities. The methods further provide for separating, identifying, and characterizing novel polymorphs of viloxazine. Further provided are methods for synthesis and identification and characterization of novel intermediates of viloxazine, as well as for some important metabolites and precursors of metabolites of viloxazine. | 05-07-2015 |
20150141645 | METHODS OF PRODUCING MOLINDONE AND ITS SALTS - The present invention is directed towards novel methods of synthesis of molindone, synthesis of the intermediates of molindone, and high-purity compositions of molindone. In particular, the invention relates to the methods of synthesis of molindone through the Mannich reaction. | 05-21-2015 |
Patent application number | Description | Published |
20080253771 | Method and apparatus for configuring Optical Network Terminals (ONT) in a network - A method and system allowing a network operator to change services on a large group of Optical Network Terminals (ONTs) at one time through the use of profiles. At least one profile is configured, and at least one of the profiles is associated with at least one Optical Network Terminal (ONT) having a number of ports. A configuration for the ONTs is generated based on the profiles and, upon a request by an ONT, the configuration is forwarded to the requesting ONT. The method and system may include a graphical user interface (GUI) for entering information used in configuring the profiles, and may assign the profiles to multiple ONTs. Further, the GUI may automatically gather and provide statistics relating to the ONTs to the network operator. Additionally, in a Session Initiation Protocol (SIP) network, the method and system may communicate with the ONTs without using a SIP protocol stack. | 10-16-2008 |
20090319666 | Method and Apparatus for Session Initiated Protocol (SIP) Based Information Uploading from an Optical Network Terminal (ONT) - Collecting diagnostic information from a remote device in today's networks is limited to system related information. However, of more interest to vendors of commercial products or services is information related to, for example, how their products, services or advertisement are perceived by end users. Accordingly, a method and corresponding apparatus according to an embodiment of the present invention are provided that extends the Session Initiated Protocol (SIP) NOTIFY mechanism. Originally defined for server to client or downstream notification of a state of a resource or of an event, the present invention extends this functionality to include uploading information other than a state of a resource or of an event from the client to the server or upstream. As such, information, such as usage behavior of a user, may now be collected to understand end user perception of products, services or advertisements. | 12-24-2009 |
20090328190 | METHOD AND APPARATUS TO PERFORM SECURITY AND VULNERABILITY TESTING OF PROTOCOLS - Flaws in information security infest modern software, and pervasive computing has made network systems vulnerable. Information security is constantly endangered by errors in protocol implementations. Testing a protocol implementation for errors directly from a network where a device implementing the protocol resides limits the coverage of protocols tested. In contrast, testing protocols from an access network that internetworks a customer premises with one or more service networks greatly expands the coverage of protocols tested. Accordingly, a method and corresponding apparatus are provided to test from the access network, testing both service network devices and customer premises devices, and the protocols implemented on those devices. | 12-31-2009 |
Patent application number | Description | Published |
20080300186 | Process to produce fibrillar proteins and method of treatment using fibrillar proteins - A method for changing a globular protein structure into a fibrillar protein structure. The method comprising the steps of providing a globular protein, forming a solution containing the globular protein, adding a detergent to the solution containing the globular protein, applying the solution to a molecular sizing column with a pore size of at least 70 kDa and eluting with a solution containing detergent. A method for changing an unfolded protein structure into a fibrillar protein structure. The method comprising the steps of providing a globular protein, forming a solution containing the globular protein, adding a urea to the solution to unfold the globular protein, applying the solution to a molecular sizing column and eluting with a solution containing detergent. A method for treating cancer comprising the steps of providing a protein, changing the protein into a fibrillar structure, and administering a therapeutically effective amount of the fibrillar structure protein to a patient in need thereof. A method for producing a vaccine adjuvant or antigen adjuvant comprising the steps of providing a protein, and changing the protein into a fibrillar structure. | 12-04-2008 |
20090263897 | REISHI F3 SUB FRACTION POLYSACCHARIDES AND METHODS OF USING SAME - The present disclosure relates to the discovery of methods of isolating subfractions of an F3 Reishi extract, and of administration of these novel isolates to eukaryotic cells in order to induce certain immumodulatory, hematopoeitic and tumor-inhibiting phenotypic changes in those eukaryotic cells, mediated through particular toll-like receptor (TLR) and other transmembrane receptors. F3 subfractions F301 and F331 have demonstrated that F331 is capable of activating at least TLR-2 while F301 is capable of activating at least TLR-2, TLR-4, and TLR-5. | 10-22-2009 |
20100183649 | METHOD OF PRODUCING VIRUS-LIKE PARTICLES OF PICORNAVIRUS USING A SMALL-UBIQUITIN-RELATED FUSION PROTEIN EXPRESSION SYSTEM - A method for producing picornaviral capsid protein complexes (e.g., picornavirus like particles) in | 07-22-2010 |
20120309682 | SUPPRESSION OF CANCER METASTASIS - Methods are provided for suppressing cancer metastasis. Cancer metastasis is the most common cause of treatment failure and death in cancer patients. Tumor cell invasion and/or migration can be significantly inhibited after fibrillar proteins (rVP1, F-HSA, and F-BSA) treatment in vitro. In addition, rVP1 can significantly suppress murine and human breast cancer metastasis and human prostate and ovarian cancer metastasis in vivo while F-HSA can significantly suppress murine breast cancer metastasis. Compositions of fibrillar proteins as anti-cancer metastasis therapeutics and methods of use thereof are provided herein. | 12-06-2012 |
20140178482 | METHOD OF PRODUCING VIRUS-LIKE PARTICLES OF PICORNAVIRUS USING A SMALL-UBIQUITIN-RELATED MODIFIER FUSION PROTEIN EXPRESSION SYSTEM - A method for producing picornaviral capsid protein complexes (e.g., picornavirus like particles) in | 06-26-2014 |
Patent application number | Description | Published |
20110144184 | PREVENTING OR TREATING VIRAL INFECTION USING AN INHIBITOR OF THE LSD1 PROTEIN, A MAO INHIBITOR OR AN INHIBITOR OF LSD1 AND A MAO INHIBITOR - An embodiment of the invention provides preventing or treating a viral infection of a host, comprising administering to the host an effective amount of an inhibitor of the protein LSD1 and/or a monoamine oxidase inhibitor. Another embodiment of the invention provides preventing or treating reactivation of a virus after latency in a host, comprising administering to the host an effective amount of an inhibitor of the protein LSD1 and/or a monoamine oxidase inhibitor. Another embodiment of the invention provides preventing or treating a viral infection in a mammal that has undergone, is undergoing, or will undergo an organ or tissue transplant, comprising administering to the mammal an effective amount of an inhibitor of the protein LSD1 and/or a monoamine oxidase inhibitor before, during, and/or after the organ or tissue transplant. The viral infection may be due to a herpesvirus, such as herpes simplex virus type 1 (HSV-1) or type 2 (HSV-2), varicella zoster virus (VZV), or cytomegalovirus (CMV). The viral infection may also be due to an adenovirus, including types 1-5. | 06-16-2011 |
20150073039 | PREVENTING OR TREATING VIRAL INFECTION USING AN INHIBITOR OF THELSD1 PROTEIN, A MAO INHIBITOR OR AN INHIBITOR OF LSD1 AND A MAOINHIBITOR - An embodiment of the invention provides a method of preventing or treating a viral infection of a host, comprising administering to the host an effective amount of an inhibitor of the protein LSD1 and/or a monoamine oxidase inhibitor. Another embodiment of the invention provides a method of preventing or treating reactivation of a virus after latency in a host, comprising administering to the host an effective amount of an inhibitor of the protein LSD1 and/or a monoamine oxidase inhibitor. Another embodiment of the invention provides a method of preventing or treating a viral infection in a mammal that has undergone, is undergoing, or will undergo an organ or tissue transplant, comprising administering to the mammal an effective amount of an inhibitor of the protein LSD1 and/or a monoamine oxidase inhibitor before, during, and/or after the organ or tissue transplant. The viral infection may be due to a herpesvirus, such as herpes simplex virus type 1 (HSV-1) or type 2 (HSV-2), varicella zoster virus (VZV), or cytomegalovirus (CMV). The viral infection may also be due to an adenovirus, including types 1-5. | 03-12-2015 |